866-997-4948(US-Canada Toll Free)

Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 110 Pages


Global Markets Directs, \'Metastatic Renal Cell Carcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma. 

Metastatic Renal Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Renal Cell Carcinoma.
  • A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Renal Cell Carcinoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Metastatic Renal Cell Carcinoma 10
Metastatic Renal Cell Carcinoma Therapeutics under Development by Companies 12
Metastatic Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Metastatic Renal Cell Carcinoma Therapeutics - Products under Development by Companies 19
Metastatic Renal Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Metastatic Renal Cell Carcinoma Therapeutics Development 22
Bristol-Myers Squibb Company 22
F. Hoffmann-La Roche Ltd. 23
Eli Lilly and Company 24
Seattle Genetics, Inc. 25
Antigenics, Inc. 26
Novartis AG 27
Eisai Co., Ltd. 28
Pfizer Inc. 29
Bayer AG 30
Bionomics Limited 31
Argos Therapeutics, Inc. 32
Angiogene Pharmaceuticals Ltd. 33
Endocyte, Inc. 34
TVAX Biomedical, LLC 35
AVEO Pharmaceuticals, Inc. 36
Metastatic Renal Cell Carcinoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
lenvatinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
regorafenib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
bevacizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
everolimus - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ramucirumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AGS-003 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
EC-17 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ZD-6126 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BNC-105P + [everolimus] - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
medroxyprogesterone - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tivozanib + [temsirolimus] - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
enzastaurin hydrochloride + [sunitinib malate] - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
bortezomib + [sorafenib tosylate] - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
lenvatinib + [everolimus] - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Autologous Tumor Lysate-Dendritic Cell Vaccine + [aldesleukin] + [bevacizumab]+ [interferon alfa-2b] - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Autologous Tumor Cell Vaccine + [aldesleukin] + [interferon alfa-2a] - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LY-2510924 + [sunitinib malate] - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
B7/IL-2 Transfected Allogeneic Tumor Cell Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
BMS-936558 + [sunitinib malate] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BEZ-235 + [everolimus] - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PF-04856884 + [axitinib] - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
B7/IL-2 Transfected Allogeneic Tumor Cell Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
TVI-Kidney-1 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
LY-2510924 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
vorsetzumab mafodotin + [everolimus] - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Romidepsin + Decitabine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
R-200 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Metastatic Renal Cell Carcinoma Therapeutics - Drug Profile Updates 87
Metastatic Renal Cell Carcinoma Therapeutics - Discontinued Products 99
Metastatic Renal Cell Carcinoma Therapeutics - Dormant Products 100
Metastatic Renal Cell Carcinoma - Product Development Milestones 103
Featured News & Press Releases 103
Oct 11, 2012: Argos Therapeutics Identifies Immune Response Marker Connected To Prolonged Overall Survival In mRCC Patients Treated With AGS-003 103
Oct 08, 2012: Argos Therapeutics Highlights Phase III ADAPT Study Of AGS-003 At 11th Annual International Kidney Cancer Symposium 104
Oct 01, 2012: GlaxoSmithKline\'s Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma 104
Aug 15, 2012: Bionomics Secures Key US Patent For Vascular Disrupting Agent BNC105 106
Feb 04, 2012: Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival In Phase II Study Of Arcelis Immunotherapy AGS-003 In Combination With Sunitinib In Patients With Metastatic Renal Cell Carcinoma 106
Feb 03, 2012: Cabozantinib Shows Encouraging Activity In Heavily Pretreated Patients With Advanced Renal Cell Carcinoma 107

Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110

List of Table


Number of Products Under Development for Metastatic Renal Cell Carcinoma, H1 2013 10
Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Comparative Analysis by Late Stage Development, H1 2013 15
Comparative Analysis by Mid Clinical Stage Development, H1 2013 16
Comparative Analysis by Early Clinical Stage Development, H1 2013 17
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Development by Companies, H1 2013 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2013 21
Bristol-Myers Squibb Company, H1 2013 22
F. Hoffmann-La Roche Ltd., H1 2013 23
Eli Lilly and Company, H1 2013 24
Seattle Genetics, Inc., H1 2013 25
Antigenics, Inc., H1 2013 26
Novartis AG, H1 2013 27
Eisai Co., Ltd., H1 2013 28
Pfizer Inc., H1 2013 29
Bayer AG, H1 2013 30
Bionomics Limited, H1 2013 31
Argos Therapeutics, Inc., H1 2013 32
Angiogene Pharmaceuticals Ltd., H1 2013 33
Endocyte, Inc., H1 2013 34
TVAX Biomedical, LLC, H1 2013 35
AVEO Pharmaceuticals, Inc., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 43
Metastatic Renal Cell Carcinoma Therapeutics - Drug Profile Updates 87
Metastatic Renal Cell Carcinoma Therapeutics - Discontinued Products 99
Metastatic Renal Cell Carcinoma Therapeutics - Dormant Products 100
Metastatic Renal Cell Carcinoma Therapeutics - Dormant Products (Contd..1) 101
Metastatic Renal Cell Carcinoma Therapeutics - Dormant Products (Contd..2) 102

List of Chart


Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2013 10
Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 14
Late Stage Products, H1 2013 15
Mid Clinical Stage Products, H1 2013 16
Early Clinical Stage Products, H1 2013 17
Pre-Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *